^
    Back
    Association details:
    Biomarker:CCDC6-RET fusion
    Cancer:Non Small Cell Lung Cancer
    Drug:Lenvima (lenvatinib) (c-KIT inhibitor, FGFR inhibitor, VEGFR inhibitor, RET inhibitor, PDGFR α antagonist)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    J Clin Oncol
    Title:

    Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry

    Excerpt:
    Responses were observed with cabozantinib, vandetanib, sunitinib, lenvatinib, and nintedanib, but not with sorafenib, alectinib, ponatinib, or regorafenib (Table 2)….Response to therapy was noted in three patients with non-KIF5B fusion partners, including two with CCDC6-RET...
    DOI:
    10.1200/JCO.2016.70.9352